News

All articles

News2 min read

Sterling expands ADC capabilities and laboratory capacity at Deeside

Sterling Pharma Solutions today announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs) facility. The project will increase the current laboratory space from 275 to 419 square meters and establish cGMP bioconjugation/ADC manufacturing capabilities.

Read more

Sterling Pharma Solutions, Manufacturer of the Year Award certificate

News2 min read

Sterling wins ‘Manufacturer of the Year’ at NEPIC annual awards 2022 Read more

Novartis' Ringaskiddy, Ireland site

News2 min read

Sterling expands global API manufacturing capabilities with acquisition of Novartis facility in Ringaskiddy, Ireland Read more

News2 min read

Biocatalysis partnership judged outstanding Read more

Cary carousel

Article2 min read

Sterling Pharma Solutions expands early phase development capabilities at Cary Read more

Biocatalysis

Article2 min read

Sterling announces exclusive partnership with the University of Manchester to develop novel route to newly approved COVID-19 therapy, Molnupiravir Read more

Dudley, Northumberland, UK API Manufacturing Site

News2 min read

Sterling announces £10m investment at Dudley, UK to increase process development and manufacturing capacity Read more

ADCs

News1 min read

Sterling recognised in best CRO category at World ADC Awards Read more

News2 min read

Sterling establishes centre of excellence in continuous flow chemistry at Dudley, UK facility Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

URL

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229